Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M08D1 in relapsed or refractory lymphoid malignancies
NCT06718634Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M08D1 in lymphoid malignancies, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
BL-M08D1
03
Conditions
lymphoid malignancies
Beyond the preview
Go deeper on NCT06718634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718634.